已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome

医学 内科学 心房颤动 心脏病学 抗血栓 急性冠脉综合征 氯吡格雷 抗血小板药物 阿司匹林 冲程(发动机) 心肌梗塞 机械工程 工程类
作者
Wen-He LV,Jianzeng Dong,Xin Du,Rong Hu,Liu He,Deyong Long,Caihua Sang,Chang‐Qi Jia,Li Feng,Li Xu,Man Ning,Xuan Chen,Yi‐Kai Cui,Ribo Tang,Changsheng Ma
出处
期刊:Journal of Thrombosis and Thrombolysis [Springer Science+Business Media]
卷期号:53 (4): 868-877 被引量:1
标识
DOI:10.1007/s11239-021-02588-z
摘要

This study aimed to explore antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation (AF) at high risk for stroke and chronic coronary syndrome (CCS) in real-world clinical practice. Patients with AF at high risk for stroke complicated with CCS from China Atrial Fibrillation Registry (CAFR) were enrolled. The patients were divided into non-antithrombotic (Non-AT) group, oral anticoagulants (OAC) group, antiplatelet therapy (APT) group (aspirin or clopidogrel), and dual antiplatelet therapy (DAPT) group (aspirin + clopidogrel) according to their antithrombotic strategies at baseline. The patients with OAC + single antiplatelet drug (14 cases) and OAC + dual antiplatelet therapy (7 cases) were excluded for the small sample size. The primary effectiveness outcome was the composite outcome of coronary events, thromboembolism, and all-cause mortality. The primary safety outcome was major bleeding events. From 2011 to 2018, 25,512 patients were included in the CARF study, 769 patients with AF at high risk for stroke and CCS were enrolled in this study. After a follow-up of 47.4 ± 25.3 months, the incidences of primary effectiveness outcome were 44.6%, 25.7%, 43.6%, and 29.1% in the four groups, respectively (P < 0.001). The incidences of primary effectiveness and all-cause mortality were both significantly lower in the OAC group than in the Non-AT group, (25.7% vs. 44.6%, HR 0.53, 95% CI 0.39–0.73, P < 0.001) and (14.6% vs. 38.5%, HR 0.36, 95%CI 0.25–0.52, P < 0.001). In multivariate analysis, age (HR 1.03, 95%CI 1.01–1.05, P = 0.015), heart failure (HR 1.67, 95%CI 1.20–2.33, P = 0.002) and OAC (HR 0.66, 95%CI 0.47–0.91, P = 0.012) were independent factors for the composite outcome. There was no significant difference in major bleeding events between the four groups. OAC monotherapy significantly reduced the primary effectiveness composite outcome and all-cause mortality in the patients with AF at high risk for stroke complicated with CCS. However, there was no significant difference in major bleeding among the different antithrombotic strategies. Trial Registration www.chictr.org.cn (No. ChiCTR-OCH-13003729).
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
生动雨安完成签到,获得积分10
刚刚
LYQ完成签到 ,获得积分10
1秒前
zxdxfbf发布了新的文献求助10
1秒前
Shaun发布了新的文献求助10
1秒前
随缘完成签到 ,获得积分10
1秒前
Akim的应助被高高采纳,获得10
2秒前
2秒前
有点帅完成签到 ,获得积分10
2秒前
4秒前
6秒前
lv完成签到,获得积分20
7秒前
7秒前
syalonyui发布了新的文献求助10
7秒前
沉默完成签到,获得积分10
7秒前
余香的应助被温暖背包采纳,获得10
8秒前
Lw完成签到,获得积分10
8秒前
可爱的函函的应助被芦苇红柳采纳,获得10
8秒前
8秒前
13秒前
bbbmmm发布了新的文献求助10
13秒前
北风发布了新的文献求助10
14秒前
14秒前
雾雪零尘发布了新的文献求助10
15秒前
季生完成签到 ,获得积分10
15秒前
15秒前
sss完成签到 ,获得积分10
16秒前
LLL完成签到 ,获得积分10
16秒前
余香的应助被许安采纳,获得10
17秒前
豆豆发布了新的文献求助10
17秒前
18秒前
21秒前
怡然青烟完成签到,获得积分10
21秒前
21秒前
23秒前
李大海完成签到,获得积分10
24秒前
加鱼发布了新的文献求助20
25秒前
孤独难胜完成签到,获得积分10
25秒前
26秒前
科研完成签到,获得积分10
28秒前
田様的应助被高高采纳,获得10
28秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1500
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
What Else Can I Tell You?: A Pragmatic Study of English Rhetorical Questions as Discursive and Argumentative Acts 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8158511
求助须知:如何正确求助?哪些是违规求助? 9554266
关于积分的说明 21718664
捐赠科研通 7747921
什么是DOI,文献DOI怎么找? 3427015
关于科研通互助平台的介绍 2551783
邀请新用户注册赠送积分活动 2471157